About CryoLife

bldg smallCryoLife, Inc. is one of the world’s contemporary medical device companies providing preserved human cardiac and vascular tissues, surgical adhesives and sealants, cardiac lasers and implantable end-stage renal disease access grafts for the repair of complex cardiac and vascular reconstruction surgeries. Since the Company’s inception in 1984, it is estimated that its products and tissues have been implanted in about 900,000 patients worldwide.

Learn More

Products and Services

vid-cardiac Cardiac Tissues
Aortic and pulmonary homografts for cardiac reconstruction
vid-vascular Vascular Tissues
Allografts for AV access, peripheral bypass, and infected fields
vid-hero HeRO® Graft
AV access solution to reduce catheter dependency
vid-bioglue BioGlue® Surgical Adhesive
The leading surgical adhesive used in cardiovascular surgery
vid-tmr Transmyocardial Revascularization
Laser therapy for ischemic heart disease
vid-perclot Perclot®
Next generation hemostat for international use only

Learn More

Features

PerClot® vs HemoStase
See how PerClot compares to HemoStase, one of the trade names used for Medafor-manufactured Arista®.
PerClot is not approved for sale in the United States
Arista is a trademark of Medafor, Inc.

Learn More

Recent News

CryoLife Receives FDA Approval to Begin Clinical Trials for PerClot® in the U.S.

The primary objective of this investigation will be to collect clinical data concerning the safety and efficacy of PerClot versus C.R. Bard’s Arista MPH Hemostat in multiple surgical disciplines when used as an adjunct to conventional means of achieving hemostasis such as pressure or ligature.

Learn More

CryoLife Continues To Support Customer Education With Third Central Venous Pathology Summit

CryoLife will host its third Central Venous Pathology (CVP) Summit on March 25-27, 2014 at CryoLife's training facility at its corporate headquarters in suburban Atlanta. The Company expects that over 80 physicians and dialysis therapy professionals will attend the CVP Summit.

Learn More

New Clinical Update from the National Kidney Foundation

Read how cryopreserved allografts can effectively manage infected AV grafts. Download the National Kidney Foundation's clinical update for more information.

Learn More
 
FacebookYoutubeLinkedin

Become a Donor and “Light Up the World”

30yrsEach year, the Donate Life Rose Parade Float serves as a memorial to organ and tissue donors, their families, living donors, and transplant recipients. This year’s theme, Light Up the World, represents the compassion and courage of those who give and receive the gift of life. Adorning the float, Donate Life America gave tribute to 81 donors with their own floragraph while 36 recipients and living donors were honored with positions to ride or walk in the parade.

CryoLife was given the exceptional privilege to announce Kevin Patrick Dobson as one of the donors to be memorialized with a floragraph. Kevin was known for his dedication and drive to help those in need. His greatest source of pride was his children, his son Kevin Patrick Dobson, Jr., daughters Jamie Kathleen and Brooke Lauren Dobson, and step-son Andrew Hastings. While serving his community as a New York State Trooper, he was struck by a passing motorist. According to his father Richard, “Kevin prayed that his donation would lessen the suffering of another family. We who loved him in life know that his prayer was answered.”

Learn More

30 Years of Restoring Lives

30yrs

Founded in 1984, CryoLife was the first biomedical company to specialize in the low temperature preservation of human heart valves used for complex cardiac reconstruction primarily in children born with heart defects. Since those initial efforts, the company’s preservation technology has expanded to include cardiac patches, saphenous veins, femoral arteries and veins as well as aorto-illiac vessels for use in central and peripheral vascular reconstruction. The company’s proprietary processes for preserving these cardiovascular tissues have dramatically improved and enhanced the lives of one hundred thousand patients primarily in North America.

Learn More